ClinicalTrials.Veeva

Menu

OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion

S

SeaSpine

Status

Completed

Conditions

Degenerative Changes
Spondylosis
Stenosis

Treatments

Procedure: Posterolateral Fusion

Study type

Interventional

Funder types

Industry

Identifiers

NCT01873586
OSX-US-2012-1

Details and patient eligibility

About

The objective of this study is to prospectively evaluate the performance of Integra's OsteoStrux Collagen Ceramic Scaffold combined with bone marrow aspirate as an adjunct for instrumented posterolateral spine fusion, as compared to local autograft.

Enrollment

29 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Are 18 (eighteen) years of age or older at the time of surgery.
  2. Require spinal fusion using TLIF, PLF or PLIF, with or without the use of an interbody spacer, at 1 to 3 levels between L3-S1.
  3. Are willing and able to return for the scheduled follow-up visits, follow post-operative instructions and undergo the required radiographic exams (A/P, Lateral Neutral and Lateral Flexion/Extension X-rays) for up to 4 time points between 3 weeks and 12 months post-surgery (3 months ± 2 weeks, 6±1 months, 12±2 months and if required 24±3 months post-surgery), including one CT-scan at 12±2 months.
  4. Are unresponsive to conservative care over a period of at least 6 months or have signs and/or symptoms that mandate urgent surgical intervention.
  5. Are willing and able to sign study specific informed consent.

Exclusion criteria

  1. Are long term users of medications (i.e. steroids greater than 8 days) that are known to inhibit fusion or bone metabolism at any time within 6 months prior to surgery. Exceptions are inhaled steroids for asthma treatment (i.e. patients on inhaled steroids are allowed), or epidural steroid injections.
  2. Are taking immunosuppressive agents (Cancer chemotherapy, treatment with Disease Modifying Anti-rheumatic drugs (DMARDs) or any similar immunomodulating drugs) or are treated with Growth Factors or Insulin at any time within 6 months prior to surgery.
  3. Are being treated with radiotherapy.
  4. Are having medical conditions, known to impact bone metabolism, such as Paget's disease, or has established osteoporosis (i.e. has had one or more fragility fractures).
  5. Are pregnant, lactating or women wishing to become pregnant.
  6. Are a prisoner.
  7. BMI ≥ 40
  8. Are smokers and/or nicotine/tobacco users
  9. Are currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the study endpoints.
  10. Had prior spine surgery at the index level except posterior decompressive surgery where the posterior elements are preserved e.g. facet saving techniques such as discectomy, laminotomy, and intradiscal procedures.
  11. Use of routine prophylactic NSAIDS for 3 months post-operatively, but low dose concomitant pain medications e.g. aspirin should be continued and recorded on the Concomitant Pain Medications case report form (CRF).

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

29 participants in 2 patient groups

OsteoStrux Collagen Ceramic Scaffold
Experimental group
Description:
OsteoStrux Collagen Ceramic Scaffold (posterolateral gutter at the symptomatic side)
Treatment:
Procedure: Posterolateral Fusion
Local autograft
Active Comparator group
Description:
Local autograft (posterolateral gutter at the contralateral side)
Treatment:
Procedure: Posterolateral Fusion

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems